HOME › Top Market Reports › Pre-Clinical Imaging (In vivo) Market – By Systems and Reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017

Pre-Clinical Imaging (In vivo) Market – By Systems and Reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017

By: marketsandmarkets.com
Publishing Date: January 2013
Report Code: MD 1515

Please click here to get the relevant report of Small Animal Imaging (In Vivo) Market - By systems and reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017

Pre-clinical imaging technologies are excellent tools for assessment of anatomical, physiological and functional parameters at molecular and cellular levels in the live animal models. It plays a significant role in the assessment of specific drug candidate or treatment regime, in phenotyping and understanding the pathophysiology of various diseases.

The global pre-clinical imaging (in vivo) market has witnessed challenging and dynamic market conditions in terms of government funding/grants and technological advancements in the last five years. The overall pre-clinical imaging (in vivo) market is valued at $790 million in 2012, and is estimated to grow at an annual growth rate of 14.5% over the next five years. Market displays growing preference for new technologies such as hybrid systems – PET + MRI, SPECT + MRI and PET + SPECT + CT, for the continuum of advantages offered by them over traditional standalone techniques as they enable to overcome limitations of each technology. Pre-clinical imaging (in vivo) industry has witnessed myriad technological advancements over the last two decades and it is expected that this trend will continue in future to solve the present challenges and fill the unmet needs of the market.

Factors such as increasing pre-clinical research studies, technological advancements, rising government support in developing markets, growing use of functional imaging, and increasing number of pharma companies and research institutions, are spurring the growth of pre-clinical imaging market. However, high cost of imaging systems and technological limitations are restraining the market growth. Market is facing some major challenges such as industry consolidation, slow adoption rate of pre-clinical imaging technologies by tier I and tier II pharma/biotech companies and lack of sufficient accessibility of radiotracers for nuclear imaging.

In 2012, North America is the biggest market, about 38.2% share of the global pre-clinical imaging (in vivo) systems and reagents market, followed by Europe. However, the Asian and Latin American countries represent the fastest growing markets due to increasing government support for research, growing number of research institution and CRO’s, and rising industry-academia partnerships for pre-clinical research. Moreover, economic slowdown, pricing pressures and high competition in mature countries will compel the companies to focus on the Asian market.

Market has opportunity for imaging systems which will be cost effective with applications in multiple fields. In addition, unique combinations of imaging modalities such as MRI and optical imaging, which will address the challenges associated with the currently marketed imaging combinations are expected to have better future prospects for growth.

Pre-clinical imaging market is highly competitive, with each player vying to make a mark and gain a large market share. Rapid industry consolidation is a burning issue in the market currently, which not only affects the small market players but also enforces big players to redefine their marketing strategies.

The key players in this market are Siemens AG (Germany), PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), Bioscan, Inc. (U.S.), Mediso Medical Imaging Systems (Hungary), Gamma Medica (U.S.), FUJIFILM Holdings Corporation (Japan), Aspect Imaging (Israel), Miltenyi Biotec GmbH (Germany), Life Technologies Corporation (U.S.), Scanco Medical (Switzerland), and Targeson, Inc. (U.S.).

TABLE OF CONTENTS

1 INTRODUCTION
    1.1 KEY TAKE-AWAYS
    1.2 REPORT DESCRIPTION
    1.3 MARKETS COVERED
    1.4 STAKEHOLDERS
    1.5 RESEARCH METHODOLOGY
         1.5.1 MARKET SIZE
         1.5.2 MARKET SHARE
         1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
         1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
         1.5.5 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
    3.1 INTRODUCTION
    3.2 MARKET SEGMENTATION
          3.2.1 PRE-CLINICAL IMAGING (IN VIVO) MARKET, BY TECHNOLOGY
          3.2.2 PRE-CLINICAL IMAGING (IN VIVO) MARKET, BY REAGENTS
    3.3 MARKET DYNAMICS
          3.3.1 DRIVERS
                  3.3.1.1 Technological Advancements
                  3.3.1.2 Growing Adoption Rate for Pre-clinical Imaging
                  3.3.1.3 Rising Application of Functional Imaging
                  3.3.1.4 Increasing Number of Pharma Companies and Research Institutions
          3.3.2 RESTRAINTS
                  3.3.2.1 High Device Cost
                  3.3.2.2 Technological Limitations
                  3.3.2.3 High Cost and Data Requirements for Bringing New Technology
          3.3.3 OPPORTUNITIES
                  3.3.3.1 Next Unique Combinations in MRI
                  3.3.3.2 High Resolution & Sensitivity of Imaging Devices with Usage in Multiple Applications
                  3.3.3.3 Emerging Markets
          3.3.4 CHALLENGES
                  3.3.4.1 Sustainability of Players in Highly Competitive Market
                  3.3.4.2 Availability of Radiopharmaceuticals
    3.4 MARKET SHARE ANALYSIS
          3.4.1 BY TECHNOLOGY
          3.4.2 BY MARKET PLAYERS
          3.4.3 BY GEOGRAPHY

4 GLOBAL PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET, BY TECHNOLOGY
    4.1 INTRODUCTION
    4.2 STANDALONE TECHNOLOGY FOR PRE-CLINICAL IMAGING (IN VIVO)
          4.2.1 NUCLEAR IMAGING
                   4.2.1.1 Micro-SPECT
                   4.2.1.2 Micro-PET
          4.2.2 OPTICAL IMAGING
                   4.2.2.1 Fluorescence
                   4.2.2.2 Bioluminescence
                   4.2.2.3 Near Infrared Fluorescence
           4.2.3 MICRO-MRI
           4.2.4 MICRO-CT
           4.2.5 MICRO-ULTRASOUND
    4.3 MULTIMODAL IMAGING FOR PRE-CLINICAL IMAGING (IN VIVO)
          4.3.1 MULTIMODAL NUCLEAR IMAGING DEVICES
                   4.3.1.1 SPECT + CT
                   4.3.1.2 SPECT + MR
                   4.3.1.3 PET + CT
                   4.3.1.4 PET + MR
                   4.3.1.5 SPECT + PET + CT
          4.3.2 MULTIMODAL OPTICAL IMAGING DEVICES
                   4.3.2.1 Optical+ X-ray + Radioisotopic

5 GLOBAL PRE-CLINICAL IMAGING (IN VIVO) MARKET, BY REAGENTS
    5.1 INTRODUCTION
    5.2 NUCLEAR IMAGING FOR PRE-CLINICAL IMAGING (IN VIVO)
          5.2.1 PET TRACERS
                   5.2.1.1 Fluorine-18 based
                   5.2.1.2 Carbon-11 based
                   5.2.1.3 Copper-64 based
                   5.2.1.4 Others
          5.2.2 SPECT PROBES
                   5.2.2.1 Technetium-99m based
                   5.2.2.2 Iodine-131 based
                   5.2.2.3 Gallium-67 based
                   5.2.2.4 Thallium-201 based
                   5.2.2.5 Others
    5.3 OPTICAL IMAGING FOR PRE-CLINICAL IMAGING (IN VIVO)
          5.3.1 BIOLUMINESCENCE
                   5.3.1.1 Luciferins
                   5.3.1.2 Proluciferins
                   5.3.1.3 Coelenterazine
                   5.3.1.4 Others
         5.3.2 FLUORESCENCE
                   5.3.2.1 Green Fluorescent Proteins
                   5.3.2.2 Red Fluorescent Proteins
                   5.3.2.3 Infrared Dyes
                   5.3.2.4 Others (Natural fluorescence Molecules such as Collagen and Elastin)
    5.4 MRI CONTRAST REAGENTS FOR PRE-CLINICAL IMAGING (IN VIVO)
         5.4.1 GADOLINIUM BASED
         5.4.2 IRON BASED
    5.5 CT CONTRAST REAGENTS FOR PRE-CLINICAL IMAGING
(IN VIVO)
         5.5.1 IODINE BASED
         5.5.2 BARIUM BASED
         5.5.3 GASTROGRAFIN BASED
    5.6 ULTRASOUND CONTRAST REAGENTS FOR PRE-CLINICAL IMAGING (IN VIVO)
         5.6.1 GADOLINIUM OXIDE ALBUMIN MICROSPHERES - GOAM

6 GEOGRAPHIC ANALYSIS
    6.1 INTRODUCTION
    6.2 NORTH AMERICA
    6.3 EUROPE
    6.4 ASIA-PACIFIC
    6.5 REST OF THE WORLD (ROW)

7 COMPETITIVE LANDSCAPE
    7.1 INTRODUCTION

8 COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, and Developments)*
    8.1 AGILENT TECHNOLOGIES, INC.
          8.1.1 OVERVIEW
          8.1.2 FINANCIALS
          8.1.3 PRODUCTS & SERVICES
          8.1.4 STRATEGY
          8.1.5 DEVELOPMENTS
    8.2 ASPECT IMAGING
          8.2.1 OVERVIEW
          8.2.2 FINANCIALS
          8.2.3 PRODUCTS & SERVICES
          8.2.4 STRATEGY
          8.2.5 DEVELOPMENTS
    8.3 BIOSCAN, INC.
          8.3.1 OVERVIEW
          8.3.2 FINANCIALS
          8.3.3 PRODUCTS & SERVICES
          8.3.4 STRATEGY
          8.3.5 DEVELOPMENTS
    8.4 BRUKER CORPORATION
          8.4.1 OVERVIEW
          8.4.2 FINANCIALS
          8.4.3 PRODUCTS & SERVICES
          8.4.4 STRATEGY
          8.4.5 DEVELOPMENTS
    8.5 FUJIFILM HOLDINGS CORPORATION
          8.5.1 OVERVIEW
          8.5.2 FINANCIALS
          8.5.3 PRODUCTS & SERVICES
          8.5.4 STRATEGY
          8.5.5 DEVELOPMENTS
    8.6 GAMMA MEDICA-IDEAS, INC.
         8.6.1 OVERVIEW
         8.6.2 FINANCIALS
         8.6.3 PRODUCTS & SERVICES
         8.6.4 STRATEGY
    8.7 GENOVIS AB
          8.7.1 OVERVIEW
          8.7.2 FINANCIALS
          8.7.3 PRODUCTS & SERVICES
          8.7.4 STRATEGY
          8.7.5 DEVELOPMENTS
    8.8 LI-COR BIOSCIENCES
          8.8.1 OVERVIEW
          8.8.2 FINANCIALS
          8.8.3 PRODUCTS & SERVICES
          8.8.4 STRATEGY
          8.8.5 DEVELOPMENTS
    8.9 LIFE TECHNOLOGIES CORPORATION
          8.9.1 OVERVIEW
          8.9.2 FINANCIALS
          8.9.3 PRODUCTS & SERVICES
          8.9.4 STRATEGY
          8.9.5 DEVELOPMENTS
    8.10 MEDISO MEDICAL IMAGING SYSTEMS
            8.10.1 OVERVIEW
            8.10.2 FINANCIALS
            8.10.3 PRODUCTS & SERVICES
            8.10.4 STRATEGY
            8.10.5 DEVELOPMENTS
    8.11 MILTENYI BIOTEC GMBH
            8.11.1 OVERVIEW
            8.11.2 FINANCIALS
            8.11.3 PRODUCTS & SERVICES
            8.11.4 STRATEGY
            8.11.5 DEVELOPMENTS
    8.12 PERKINELMER, INC.
            8.12.1 OVERVIEW
            8.12.2 FINANCIALS
            8.12.3 PRODUCTS & SERVICES
            8.12.4 STRATEGY
            8.12.5 DEVELOPMENTS
    8.13 PROMEGA CORPORATION
            8.13.1 OVERVIEW
            8.13.2 FINANCIALS
            8.13.3 PRODUCTS & SERVICES
            8.13.4 STRATEGY
            8.13.5 DEVELOPMENTS
    8.14 SCANCO MEDICAL AG
            8.14.1 OVERVIEW
            8.14.2 FINANCIALS
            8.14.3 PRODUCTS & SERVICES
            8.14.4 STRATEGY
            8.14.5 DEVELOPMENTS
    8.15 SIEMENS AG
            8.15.1 OVERVIEW
            8.15.2 FINANCIALS
            8.15.3 PRODUCTS & SERVICES
            8.15.4 STRATEGY
            8.15.5 DEVELOPMENTS
    8.16 SOFIE BIOSCIENCES, INC.
            8.16.1 OVERVIEW
            8.16.2 FINANCIALS
            8.16.3 PRODUCTS & SERVICES
            8.16.4 STRATEGY
            8.16.5 DEVELOPMENTS
    8.17 TARGESON, INC.
            8.17.1 OVERVIEW
            8.17.2 FINANCIALS
            8.17.3 PRODUCTS & SERVICES
            8.17.4 STRATEGY
            8.17.5 DEVELOPMENTS
    8.18 UVP, LLC.
            8.18.1 OVERVIEW
            8.18.2 FINANCIALS
            8.18.3 PRODUCTS & SERVICES
            8.18.4 STRATEGY
            8.18.5 DEVELOPMENTS

LIST OF TABLES

TABLE 1 GLOBAL PRE-CLINICAL IMAGING (IN VIVO) MARKET REVENUE, BY SEGMENTS, 2010 – 2017 ($MILLION)
TABLE 2 GLOBAL PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 3 PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 4 GLOBAL PRE-CLINICAL STANDALONE SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 5 PRE-CLINICAL STANDALONE SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 6 GLOBAL PRE-CLINICAL STANDALONE NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 7 PRE-CLINICAL STANDALONE NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 8 PRE-CLINICAL MICRO-SPECT SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 9 PRE-CLINICAL MICRO-PET SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 10 GLOBAL PRE-CLINICAL OPTICAL IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 11 PRE-CLINICAL OPTICAL IMAGING SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 12 PRE-CLINICAL FLUORESCENCE SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 13 PRE-CLINICAL BIOLUMINESCENCE SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 14 PRE-CLINICAL NEAR INFRARED FLUORESCENCE SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 15 PRE-CLINICAL MICRO-MRI SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 16 PRE-CLINICAL MICRO-CT SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 17 PRE-CLINICAL MICRO-ULTRASOUND SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 18 PRE-CLINICAL MULTIMODAL NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 19 PRE-CLINICAL MULTIMODAL NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 20 PRE-CLINICAL SPECT/CT SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 21 PRE-CLINICAL SPECT/MRI SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 22 PRE-CLINICAL PET/CT SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 23 PRE-CLINICAL PET/MRI SYSTEMS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 24 GLOBAL PRE-CLINICAL IMAGING AGENTS & RADIOTRACERS SYSTEMS MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)
TABLE 25 PRE-CLINICAL IMAGING AGENTS & RADIOTRACERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 GLOBAL PRE-CLINICAL NUCLEAR IMAGING RADIOTRACERS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 27 PRE-CLINICAL NUCLEAR IMAGING RADIOTRACERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 28 GLOBAL PRE-CLINICAL PET RADIOTRACERS MARKET REVENUE, BY RADIOISOTOPES, 2010 – 2017 ($MILLION)
TABLE 29 PRE-CLINICAL PET RADIOTRACERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 30 EXAMPLES OF PET TRACERS USED IN ANIMAL IMAGING
TABLE 31 PRE-CLINICAL FLUORINE-18 BASED RADIOTRACERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 32 PRE-CLINICAL CARBON-11 BASED RADIOTRACERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 33 PRE-CLINICAL COPPER-64 BASED RADIOTRACERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 34 PRE-CLINICAL OTHER PET RADIOTRACERS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 35 GLOBAL PRE-CLINICAL SPECT PROBES MARKET REVENUE, BY RADIOISOTOPES, 2010 – 2017 ($MILLION)
TABLE 36 PRE-CLINICAL SPECT PROBES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 37 PRE-CLINICAL TECHNETIUM-99M BASED PROBES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 38 PRE-CLINICAL IODINE-131 BASED PROBES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 39 PRE-CLINICAL GALLIUM-67 BASED PROBES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 40 PRE-CLINICAL THALLIUM-201 BASED PROBES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 41 PRE-CLINICAL OTHER SPECT PROBES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 42 GLOBAL PRE-CLINICAL OPTICAL IMAGING REAGENTS MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)
TABLE 43 PRE-CLINICAL OPTICAL IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 44 GLOBAL PRE-CLINICAL BIOLUMINESCENT AGENTS MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)
TABLE 45 PRE-CLINICAL BIOLUMINESCENT AGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 46 PRE-CLINICAL LUCIFERINS IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 47 PRE-CLINICAL PROLUCIFERINS IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 48 PRE-CLINICAL COELENTERAZINE IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 49 PRE-CLINICAL OTHER BIOLUMINESCENT IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 50 GLOBAL FLUORESCENT IMAGING REAGENTS MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)
TABLE 51 PRE-CLINICAL FLUORESCENT IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 52 PRE-CLINICAL GREEN FLUORESCENT PROTEINS IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 53 PRE-CLINICAL RED FLUORESCENT PROTEINS IMAGING REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 54 PRE-CLINICAL INFRARED DYES MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 55 PRE-CLINICAL OTHER FLUORESCENT IMAGING AGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 56 GLOBAL PRE-CLINICAL MRI CONTRAST REAGENTS MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)
TABLE 57 PRE-CLINICAL MRI CONTRAST REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 58 PRE-CLINICAL GADOLINIUM-BASED MRI IMAGING AGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 59 PRE-CLINICAL IRON-BASED MRI IMAGING AGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 60 GLOBAL PRE-CLINICAL CT CONTRAST REAGENTS MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)
TABLE 61 PRE-CLINICAL CT CONTRAST REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 62 PRE-CLINICAL IODINE-BASED CT IMAGING AGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 63 PRE-CLINICAL BARIUM-BASED CT IMAGING AGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 64 PRE-CLINICAL GASTROGRAFIN-BASED CT IMAGING AGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 65 PRE-CLINICAL ULTRASOUND CONTRAST REAGENTS MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 66 PRE-CLINICAL IMAGING (IN VIVO) MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 67 NORTH AMERICA: PRE-CLINICAL IMAGING (IN VIVO) MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 68 NORTH AMERICA: PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 69 NORTH AMERICA: PRE-CLINICAL STANDALONE IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 70 NORTH AMERICA: PRE-CLINICAL STANDALONE NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 –2017 ($MILLION)
TABLE 71 NORTH AMERICA: PRE-CLINICAL OPTICAL IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 72 NORTH AMERICA: PRE-CLINICAL IMAGING AGENTS & RADIOTRACERS MARKET REVENUE, 2010 – 2017 ($MILLION)
TABLE 73 EUROPE: PRE-CLINICAL IMAGING (IN VIVO) MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 74 EUROPE: PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 75 EUROPE: PRE-CLINICAL STANDALONE IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 76 EUROPE: PRE-CLINICAL STANDALONE NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 77 EUROPE: PRE-CLINICAL OPTICAL IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 78 EUROPE: PRE-CLINICAL IMAGING AGENTS & RADIOTRACERS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 79 ASIA-PACIFIC: PRE-CLINICAL IMAGING (IN VIVO) MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 80 ASIA-PACIFIC: PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 81 ASIA-PACIFIC: PRE-CLINICAL STANDALONE IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 82 ASIA-PACIFIC: PRE-CLINICAL STANDALONE NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 83 ASIA-PACIFIC: PRE-CLINICAL OPTICAL IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 84 ASIA-PACIFIC: PRE-CLINICAL IMAGING AGENTS & RADIOTRACERS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 85 ROW: PRE-CLINICAL IMAGING (IN VIVO) MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 86 ROW: PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 87 ROW: PRE-CLINICAL STANDALONE IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 88 ROW: PRE-CLINICAL STANDALONE NUCLEAR IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 89 ROW: PRE-CLINICAL OPTICAL IMAGING SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 90 ROW: PRE-CLINICAL IMAGING AGENTS & RADIOTRACERS MARKET REVENUE, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 91 MERGERS & ACQUISITIONS, 2010 –2012
TABLE 92 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2012
TABLE 93 NEW PRODUCT LAUNCH, 2009 – 2012
TABLE 94 EXPANSION, 2010 – 2012
TABLE 95 OTHER DEVELOPMENTS, 2009 –2012
TABLE 96 AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 97 AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 98 AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 99 BRUKER CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION)
TABLE 100 BRUKER CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION
TABLE 101 BRUKER CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 102 BRUKER CORPORATION: TOTAL REVENUE, BY SCIENTIFIC INSTRUMENTS SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 103 BRUKER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 104 FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
TABLE 105 FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2010 – 2012 ($MILLION)
TABLE 106 FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 107 GENOVIS AB: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($THOUSAND)
TABLE 108 GENOVIS AB: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($THOUSAND)
TABLE 109 LIFE TECHNOLOGIES CORPORATION: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 110 LIFE TECHNOLOGIES CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 111 LIFE TECHNOLOGIES CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 112 PERKINELMER INC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 113 PERKINELMER INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 114 PERKINELMER, INC: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 115 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 116 SIEMENS AG: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 117 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)

LIST OF FIGURES

FIGURE 1 GLOBAL PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET, BY TECHNOLOGY, 2012 VS 2017
FIGURE 2 GLOBAL PRE-CLINICAL IMAGING (IN VIVO) REAGENTS MARKET, BY TECHNOLOGY, 2012 VS 2017
FIGURE 3 PRE-CLINICAL IMAGING (IN VIVO) MARKET, BY GEOGRAPHY, 2012
FIGURE 4 PRE-CLINICAL IMAGING (IN VIVO) TECHNOLOGIES MARKET SEGMENTATION
FIGURE 5 PRE-CLINICAL IMAGING (IN VIVO) MARKET SEGMENTATION
FIGURE 6 PRE-CLINICAL IMAGING (IN VIVO) SYSTEMS MARKET SEGMENTATION
FIGURE 7 COMPARATIVE CHART ON PRE-CLINICAL IMAGING (IN VIVO) MODALITIES
FIGURE 8 PRE-CLINICAL IMAGING (IN VIVO) REAGENTS MARKET SEGMENTATION
FIGURE 9 MARKET DYNAMICS
FIGURE 10 GLOBAL PRE-CLINICAL IMAGING MARKET SHARE, BY TECHNOLOGY, 2012
FIGURE 11 GLOBAL PRE-CLINICAL IMAGING MARKET SHARE, BY KEY PLAYERS, 2012
FIGURE 12 GLOBAL PRE-CLINICAL NUCLEAR IMAGING MARKET SHARE, BY KEY PLAYERS, 2012
FIGURE 13 GLOBAL PRE-CLINICAL OPTICAL IMAGING MARKET SHARE, BY KEY PLAYERS, 2012
FIGURE 14 PRE-CLINICAL IMAGING SYSTEMS & REAGENTS MARKET SHARE, BY GEOGRAPHY, 2012 VS. 2017
FIGURE 15 GLOBAL PRE-CLINICAL STANDALONE SYSTEMS MARKET REVENUE, BY TECHNOLOGY, 2012 VS 2017 ($MILLION)
FIGURE 16 GLOBAL PRE-CLINICAL IMAGING REAGENTS & RADIOTRACERS SYSTEMS MARKET REVENUE, BY PRODUCTS, 2010 – 2017 ($MILLION)
FIGURE 17 GLOBAL PRE-CLINICAL IMAGING (IN VIVO) MARKET SHARE, BY GROWTH STRATEGIES, 2010 – 2012
FIGURE 18 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY, 2010 – 2012
FIGURE 19 KEY PLAYERS FOCUSING ON PARTNERSHIPS & COLLABORATIONS STRATEGY, 2010 – 2012
FIGURE 20 KEY PLAYERS FOCUSING ON MERGERS & ACQUISITIONS STRATEGY, 2010 – 2012

*Details on financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

Pre-clinical in vivo imaging is a procedure used in the visualization of animal models research purposes. It helps in the refinement of animal models by enabling longitudinal studies, which allow non invasive monitoring of disease progression in real time. It is gaining high importance in the process of drug development, in order to understand the potential candidates early and to reduce wastage of time and capital on non-promising molecules.

This report covers two types of imaging systems, namely, standalone and multimodal imaging technologies. In addition, report covers different types of imaging reagents employed in pre-clinical research studies such as nuclear imaging reagents, optical imaging reagents, MRI contrasting reagents, CT contrast reagents and ultrasound contrast reagents. With the diverse choice of imaging technologies, parameters such as disease model, cost, ease of use, accessibility to imaging agents, and utility of particular imaging modality, play crucial role in dictating researcher’s choice while purchasing an imaging system.

In this report we also have covered imaging systems and reagents for the technologies such as micro-SPECT, micro-PET, optical imaging, micro-MRI, micro-CT and micro-ultrasound. Each technology is different from other with respect to parameters such as image acquisition time, sensitivity, specificity, image resolution, user-friendliness and cost. Pre-clinical imaging (in vivo) market, which consists of a wide range of imaging systems and reagents, is steered by forces that vary with respect to difference in government support for pre-clinical research across different regions; backed by other factors such as economic status, intensity of competition, number of research institutions and CROs, accessibility to radio isotopes, and regulatory policies.

The global pre-clinical imaging (in vivo) market is estimated at $789.4 million in 2012 and is poised to grow at a CAGR of 14.5% to reach $1,551.7 million by 2017.

Technological advancements, growing adoption rate, rising application of functional imaging and increasing number of pharma companies are the major driving factors that are enhancing the growth of the market. High device cost and technological limitations are the factors hindering the market growth. Next unique combinations in MRI, High resolution & sensitivity of imaging devices with usage in multiple applications, emerging markets are the factors that seem to be favorable opportunities to the market. Whereas, sustainability of players in highly competitive environment and availability of radiopharmaceuticals are the major challenges that are faced by the pre-clinical imaging (in vivo) market.

Scope of the Report

Global pre-clinical imaging (in vivo) market, by Technology:

Standalone Technology
- Nuclear imaging
  - MicroSPECT (Single photon emission computed tomography)
  - MicroPET (Positron emission tomography)
- Optical imaging
  - Fluorescence
  - Bioluminescence
  - Near Infrared fluorescence
- Micro-MRI
- Micro-CT
- Micro-Ultrasound
Multimodality Technology
- Multimodal Nuclear imaging devices
  - SPECT+CT
  - SPECT+MR
  - PET+CT
  - PET+MR
  - SPECT+PET+CT
- Multimodal Optical imaging devices
  - Optical + X-ray+ Radioisotopic

Global pre-clinical imaging (in vivo) market, by reagents:

Nuclear imaging
- PET Tracers
  - Fluorine-18 based
  - Carbon-11 based
  - Copper-64 based
  - Others
- SPECT probes
  - Technetium-99m based
  - Iodine-131 based
  - Gallium-67 based
  - Thallium-201 based
  - Others
Optical imaging
- Bioluminescence
  - Luciferins
  - Proluciferins
  - coelenterazine
  - Others
- Fluoresence
  - Green fluorescent proteins
  - Red fluorescent proteins
  - Infrared dyes
  - Others (natural fluoresence molecules such as collagen and elastin)
MRI contrasting reagents
- Gadolinium based
- Iron based
CT contrast reagents
- Iodine based
- Barium based
- Gastrografin based
Ultrasound contrast reagents